Episode Outline:

Issues

      - Government through NIH grants provides money for investigators to find new drugs

      - PhRMA takes these findings and builds new drugs

      - Taxpayers don’t benefit from innovation, but pay high prices for drugs

      - Safe harbors for physicians and pharmacist who participates in studies

      - Safe harbor for physicians and pharmacist who participate in studies

PhRMA Issues

      - Development to production is costly

      - Research leads to many failures

      - Patent monopolies

      - Marketing is costly

Remember who benefits

      - Rare for counties to participate in profits of new drugs, either directly or indirectly

      - Universities profit from new drugs

      - Countries may provide tax incentives to help drug industry develop cheaper alternatives. 

_______

Make sure to subscribe to get the latest episode. 

Contact Us:

Email: [email protected]

Website: http://www.propharmaconsultants.com/

Facebook: https://www.facebook.com/propharmainc

Twitter: https://twitter.com/ProPharma

Instagram: https://www.instagram.com/propharmainc/

LinkedIn: https://www.linkedin.com/company/pro-pharma-pharmaceutical-consultants-inc/

Podcast: https://anchor.fm/pro-pharma-talks

YouTube: https://www.youtube.com/user/ProPharmaEducation

 Pro Pharma Talks - Episode 002

Topic: Skinny Health Plans

Episode Outline:

1. Skinny Health Plans = Short Term Health Plans

   -Sell for 365 days up from 90 days

   -Renew for 36 months

   -High Out-of-Pocket (OOP) Expenses

   -Premium = 20% of lowest priced ACA Bronze Plan

   -Don't Cover Pre-Existing Conditions

2. Benefits are Restricted

   -Don't C over:

        -1. Maternity Care

        -2. Outpatient Prescription Drugs

        -3. Substance Abuse

        -4. Mental Health Treatment

3. Impact on ACA Plans

   -Higher Costs:

        -CMS Projected 1% Increase

        -Urban Institute 18% Increase

   -Injured Individuals will return to ACA - leading to higher costs

   -Brokers make 20% commissions on Skinny vs. 5% on ACA

4. Remember 

   -Skinny = Lower Cost/ Higher OOP

   -Prohibit Underwriting = Pre-Existing Conditions NOT COVERED

   -Outpatient prescription Medications NOT COVERED

   -Brokers Make MORE Selling Skinny

_______

Make sure to subscribe to get the latest episode. 

Contact Us:

Email: [email protected]

Website: http://www.propharmaconsultants.com/

Facebook: https://www.facebook.com/propharmainc

Twitter: https://twitter.com/ProPharma

Instagram: https://www.instagram.com/propharmainc/

LinkedIn: https://www.linkedin.com/company/pro-pharma-pharmaceutical-consultants-inc/

Podcast: https://anchor.fm/pro-pharma-talks

YouTube: https://www.youtube.com/user/ProPharmaEducation

Pro Pharma Talks - Episode 001

Topic: What to Expect in 2019

Healthcare

1. Uncertainty vs. Stabilization of the Healthcare Market

2. Healthcare: Volume vs Value

3. Consolidation of Stakeholders

4. Retail"ization" of Healthcare Delivery

Drug Pricing

1. Drug Pricing Transparency

2. Drug Price Vs. Value

3. Specialty Drug Cost vs. Value

4. International Drug Pricing vs. US innovation Pricing

_______

Make sure to click that subscribe button and click the bell icon to receive notifications when we post new videos.

Contact Us:

Email: [email protected]

Website: http://www.propharmaconsultants.com/

Facebook: https://www.facebook.com/propharmainc

Twitter: https://twitter.com/ProPharma

Instagram: https://www.instagram.com/propharmainc/

LinkedIn: https://www.linkedin.com/company/pro-pharma-pharmaceutical-consultants-inc/

Podcast: https://anchor.fm/pro-pharma-talks

YouTube: https://www.youtube.com/user/ProPharmaEducation